Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Mallinckrodt to Present at Jefferies London Healthcare Conference PR Newswire DUBLIN, Nov. 14, 2024 DUBLIN, Nov. 14, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical...
Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance PR Newswire DUBLIN, Nov. 5, 2024 Achieves Third Quarter Net Sales of $505.5 Million, Reflecting...
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting PR Newswire DUBLIN, Oct. 30, 2024 –...
Mallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE™ DS Delivery System in U.S. Hospitals PR Newswire DUBLIN, Oct. 10, 2024 – The INOmax EVOLVE DS is our next-generation nitric...
Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use® Certification of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled...
THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR) PR Newswire DUBLIN, Sept. 3, 2024 – THERAKOS, the world's only fully...
Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance PR Newswire DUBLIN, Aug. 6, 2024 Achieves Second Quarter Net Sales of $514.3 Million, Reflecting...
Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector in the U.S. PR Newswire DUBLIN, Aug. 6, 2024 – Acthar Gel is the...
Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million PR Newswire DUBLIN and LUXEMBOURG, Aug. 5, 2024 Divestiture Advances Mallinckrodt's Strategic Priorities to...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
